You are here: Industry Insights > biosimilar

News List

Australia gives its nod to Trastuzumab Biosimilar biospectrumasia
August 10, 2018
The trastuzumab biosimilar will join 2 other anticancer biosimilars on the list of TAG’s approved biosimilars.
EC approves Pfizer's Herceptin biosimilar pharmatimes
August 02, 2018
Pfizer's Herceptin (trastuzumab) biosimlar Trazimera has been approved by the European Comission.
EC approves Pfizer's Herceptin biosimilar pharmatimes
August 01, 2018
Pfizer's Herceptin (trastuzumab) biosimlar Trazimera has been approved by the European Comission.
CHMP recommend white blood cell growth stimulator biosimilar to EMA pharmafile
July 31, 2018
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of two separate biosimilar versions of California-based biopharmaceutical company, Amgen’s Neulasta (pegfilgrastim).
Bayer to stop Essure sales at year-end biospectrumasia
July 24, 2018
The birth control treatment is alleged to have harmed thousands of women in the past two decades.
Pfizer bags approval for Neupogen biosimilar pharmatimes
July 24, 2018
Pfizer’s Neupogen biosimilar Nivestym has been approved by the US Food and Drug Administration and is expected to hit the market at a “significant discount” to its reference drug.
Napp secures distribution rights to Celltrion’s Herzuma pharmatimes
July 23, 2018
Napp Pharmaceuticals has secured itself exclusive UK distribution rights to Celltrion Healthcare’s Herceptin biosimilar Herzuma.
EU nod for Sandoz’ Remicade biosimilar Zessly pharmatimes
July 11, 2018
The European Commission has green-lighted Novartis unit Sandoz’ Zessly, a biosimilar version of Johnson & Johnson and Merck's Remicade.
Future growth of Lupin with complex generics, biosimilar and speciality medicines biospectrumasia
June 11, 2018
Lupin is planning to invest heavily in developing high barrier products in complex generics
Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval fiercepharma
June 06, 2018
With an FDA approval for Fulphila, the first U.S. biosimilar to Amgen's Neulasta, Mylan will have its chance to launch a biosim to one of the biggest drug targets in the U.S. market.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page